Skip to content
DataLookout
Menu

NCT07377539

A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Food Effect of JZP047 in Healthy Participants

StatusActive, Not Recruiting
PhasePhase 1
Primary completion (estimated)

At risk: Primary completion moved at least 4 months later.

Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 3 versions: 3 with changes below. See every version on ClinicalTrials.gov ↗

  1. Notable Eligibility criteria expanded, about 17 words Show 4 more changesShow less
    • Enrollment closed, study ongoing
    • Primary and study completion pushed from Jul 5, 2026 to Nov 30, 2026
    • Study description revised
    • Site details revised
  2. Notable Recruitment opened
    • Study sites: 0 to 1
    v2
  3. Study First Submitted
  • Notable: the plan changed

Endpoints

Primary

Number of Participants Reporting Treatment-emergent Adverse Events (Part A)
Timeframe: Baseline up to Day 90
Number of Participants Reporting Treatment-emergent Adverse Events (Part B)
Timeframe: Baseline up to Day 90
Number of Participants Who Discontinued The Study (Part A)
Timeframe: Baseline up to Day 90
Number of Participants Who Discontinued The Study (Part B)
Timeframe: Baseline up to Day 90
Pharmacokinetic Parameter Maximum Concentration (Part A)
Timeframe: Up to 90 days
Pharmacokinetic Parameter Time to Maximum Concentration and Time Before the Start of Absorption (Part A)
Timeframe: Up to 90 days
Pharmacokinetic Parameter Terminal Elimination Half-life (Part A)
Timeframe: Up to 90 days
Pharmacokinetic Parameter Terminal Elimination Rate Constant (Part A)
Timeframe: Up to 90 days
Pharmacokinetic Parameter Volume of Distribution During Terminal Phase (Part A)
Timeframe: Up to 90 days
Pharmacokinetic Parameter Oral Clearance (Part A)
Timeframe: Up to 90 days
Pharmacokinetic Parameter Area Under the Concentration-Time Curve (Part A)
Timeframe: Up to 90 days
Pharmacokinetic Parameter Percentage of The Area Under the Concentration-Time Curve From Time Infinity Due to Extrapolation From The Last Quantifiable Concentration to Time Infinity (Part A)
Timeframe: Up to 90 days

Secondary (4)

Dose Proportionality of JZP047 Cmax (Part A)
Dose Proportionality of JZP047 AUC0-last and AUC∞
The Effect of Food On The Single Dose PK of JZP047 Cmax
The Effect of Food On The Single Dose PK of JZP047 AUC0-last and AUC∞

Arms and interventions

Part A: JZP047Experimental

Healthy participants who are randomized to JZP047.

Part A: PlaceboPlacebo comparator

Healthy participants who are randomized to placebo.

Part B: JZP047Experimental

Healthy participants who will receive JZP047.

Drugs: JZP047

Other: Placebo

Sites

1 site in 1 country

  • Celerion, Inc.Lincoln, Nebraska, United States